Gynecologic Oncology Trial and Investigation Consortium GOTIC-002

Size: px

Start display at page:

Download "Gynecologic Oncology Trial and Investigation Consortium GOTIC-002"

れれめいこ
5 years ago
Views:

1 Gynecologic Oncology Trial and Investigation Consortium GOTIC-002

4 3 8

48 1) 2) : ) Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med. 1999;340(15): ) Noda K, Ohashi Y, Sugimori H, Ozaki M, Niibe H, Ogita S et al. Phase III double-blind randomized traial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100:treatment with immunomodulator, more is not better. Gynecol Oncol. 2006;101(3): ),,,,,,,,,,,,,,,,,,, ) Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94: ) Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al. A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung. N Engl J Med 2004; 350: ) Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. Adjuvant Chemotherapy with Uracil-Tegafur for Pathological Stage III Rectal Cancer after Mesorectal Excision with Selective Lateral Pelvic Lymphadenectomy: A Multicenter Randomized Controlled Trial. Jpn J Clin Oncol 2006; 36(4): ) Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicanter prospective randomized trial. Langenbeck s Arch Surg 2002; 386: ) Kadumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugimachi K et al. Meta-Analysis of Five Studies on Tegafur plus Uracil (UFT) as Post-Operative Adjuvant Chemotherapy for Breast Cancer. Oncology

49 2003; 64: ) Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K et al. Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials. J Clin Oncol 2005; 23(10): ) Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: ) Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K et al. γ-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001; 4: ) Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 46: ) Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. The Breast 2005; 146: ),,,,, :, (4): ) Kasumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugimachi K, Nakazato H, Abe O. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer.oncology. 2003;64(2): ) Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol. 2009;27(9): ) Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, Higaki K, Ogita M, Asaga T, Inaji H, Komichi H, Kohno N, Yamazaki K, Tanaka F, Ito T,

50 Nishikawa H, Osaki A, Koyama H, Suzuki T. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. Br J Cancer. 2009;101(4):

橡

TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1